FARABEGOLI, FULVIA
FARABEGOLI, FULVIA
FABIT - DIPARTIMENTO DI FARMACIA E BIOTECNOLOGIE
FARABEGOLI F.; F .FARABEGOLI; FARABEGOLI FU
Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity
2025 Masi, Mirco; Poppi, Laura; Previtali, Viola; Nelson, Shannon R; Wynne, Kieran; Varignani, Giulia; Falchi, Federico; Veronesi, Marina; Albanesi, Ennio; Tedesco, Daniele; De Franco, Francesca; Ciamarone, Andrea; Myers, Samuel H; Ortega, Jose Antonio; Bagnolini, Greta; Ferrandi, Giovanni; Farabegoli, Fulvia; Tirelli, Nicola; Di Stefano, Giuseppina; Oliviero, Giorgio; Walsh, Naomi; Roberti, Marinella; Girotto, Stefania; Cavalli, Andrea
Differential enantiomers activity of ARN24089 to achieve synthetic lethality in pancreatic cancer
2024 Previtali, Viola; Masi, Mirco; Poppi, Laura; Varignani, Giulia; Falchi, Federico; Tedesco, Daniele; Wynne, Kieran; Oliviero, Giorgio; Bagnolini, Greta; Farabegoli, Fulvia; DI STEFANO, Giuseppina; Girotto, Stefania; Roberti, Marinella; Cavalli, Andrea
A RAD51/BRCA2 small molecule inhibitor enhances the antineoplastic effect of the PARPi talazoparib in pancreatic cancer
2023 Laura Poppi, Samuel H Myers, Viola Previtali, Francesco Rinaldi, Fulvia Farabegoli, Giuseppina Di Stefano, Naomi Walsh, Marinella Roberti, Andrea Cavalli
An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer
2023 Myers, S. H.; Poppi, L.; Rinaldi, F.; Veronesi, M.; Ciamarone, A.; Previtali, V.; Bagnolini, G.; Schipani, F.; Ortega Martínez, J. A.; Girotto, S.; Di Stefano, G.; Farabegoli, F.; Walsh, N.; De Franco, F.; Roberti, M.; Cavalli, A.
Large Population Of Homogeneous Spheroids Models For Testing Toxicity And Diffusion Of Nanomaterials
2023 Emanuela Mensà, Ottavia Tartagni, Fulvia Farabegoli, Renato Brandimarti, Dario De Biase, Giampaolo Zuccheri
Proteomic profile of BxPC-3 cells after treatment with BRC4
2023 Viola Previtali, Samuel H. Myers, Laura Poppi, Kieran Wynne, Irene Casamassima Stefania Girotto, Giuseppina Di Stefano, Fulvia Farabegoli, Marinella Roberti, Giorgio Oliviero, Andrea Cavalli
Epigallocatechin-3-Gallate (EGCG) Mitigates Endothelial and Circulating Cells Alterations Following PLLA Electrospun Mat Placement
2022 Carmen Ciavarella, Ilenia Motta, Santino Blando, Sabrina Valente, Fulvia Farabegoli, Maria Letizia Focarete, Mauro Gargiulo, Gianandrea Pasquinelli
Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines
2022 Farabegoli F.; Granja A.; Magalhaes J.; Purgato S.; Voltattorni M.; Pinheiro M.
Epigallocatechin-3-Gallate Delivery in Lipid-Based Nanoparticles: Potentiality and Perspectives for Future Applications in Cancer Chemoprevention and Therapy
2022 Farabegoli, Fulvia; Pinheiro, Marina
Lactate is a potential promoter of tamoxifen resistance in MCF7 cells
2022 Rossi V.; Govoni M.; Farabegoli F.; Di Stefano G.
The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination
2022 Schipani, Fabrizio; Manerba, Marcella; Marotta, Roberto; Poppi, Laura; Gennari, Arianna; Rinaldi, Francesco; Armirotti, Andrea; Farabegoli, Fulvia; Roberti, Marinella; Di Stefano, Giuseppina; Rocchia, Walter; Girotto, Stefania; Tirelli, Nicola; Cavalli, Andrea
Molecules Present in Plant Essential Oils for Prevention and Treatment of Colorectal Cancer (CRC)
2021 Petrocelli, Giovannamaria; Farabegoli, Fulvia; Valerii, Maria Chiara; Giovannini, Catia; Sardo, Alberto; Spisni, Enzo
EGCG mediated targeting of deregulated signaling pathways and non-coding rnas in different cancers: Focus on JAK/STAT, Wnt/β-catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways
2020 Farooqi A.A.; Pinheiro M.; Granja A.; Farabegoli F.; Reis S.; Attar R.; Sabitaliyevich U.Y.; Xu B.; Ahmad A.
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
2020 Bagnolini G.; Milano D.; Manerba M.; Schipani F.; Ortega J.A.; Gioia D.; Falchi F.; Balboni A.; Farabegoli F.; De Franco F.; Robertson J.; Pellicciari R.; Pallavicini I.; Peri S.; Minucci S.; Girotto S.; Di Stefano G.; Roberti M.; Cavalli A.
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in anticancer therapy
2019 Bagnolini, Greta; Balboni, Andrea; Manerba, Marcella; Farabegoli, Fulvia; DI STEFANO, Giuseppina; Roberti, Marinella; Cavalli, Andrea
Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells
2019 Roberti, Marinella; Schipani, Fabrizio; Bagnolini, Greta; Milano, Domenico; Giacomini, Elisa; Falchi, Federico; Balboni, Andrea; Manerba, Marcella; Farabegoli, Fulvia; Francesca De Franco, ; Robertson, Janet; Minucci, Saverio; Pallavicini, Isabella; DI STEFANO, Giuseppina; Girotto, Stefania; Pellicciari, Roberto; and Andrea Cavalli, ; Cavalli, Andrea
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in cancer treatment
2018 Bagnolini, Greta; Balboni, Andrea; Farabegoli, Fulvia; DI STEFANO, Giuseppina; Roberti, Marinella; Cavalli, Andrea
Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro
2018 Farabegoli, Fulvia*; Govoni, Marzia; Spisni, Enzo; Papi, Alessio
Betalains increase vitexin-2-O-xyloside cytotoxicity in CaCo-2 cancer cells
2017 Farabegoli, F.; Scarpa, E.S.; Frati, A.; Serafini, G.; Papi, A.; Spisni, E.; Antonini, E.; Benedetti, S.; Ninfali, P
Design and synthesis of BRCA2-RAD51 disruptors to induce synthetic lethality in anticancer therapy
2017 Bagnolini, Greta; Falchi, F.; Farabegoli, F.; Di Stefano, G.; Roberti, M.; Cavalli, A.